| pubmed-article:7518482 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7518482 | lifeskim:mentions | umls-concept:C0879551 | lld:lifeskim |
| pubmed-article:7518482 | lifeskim:mentions | umls-concept:C0014294 | lld:lifeskim |
| pubmed-article:7518482 | lifeskim:mentions | umls-concept:C1948027 | lld:lifeskim |
| pubmed-article:7518482 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:7518482 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7518482 | pubmed:dateCreated | 1994-8-12 | lld:pubmed |
| pubmed-article:7518482 | pubmed:abstractText | Leucine enkephalin (Leu-enk) was coupled to both T and B cell antibodies in order to investigate the possibility of enhanced immunogenicity via targeted immunization. The two antibodies used were Hm x Mo CD3 and Gt x Mo Ig, respectively. The data indicate that while both antibody carriers enhanced the immunogenicity of Leu-enk, the use of the Hm x Mo CD3 antibody resulted in a greater number of mice with positive Leu-enk specific serum titers. 12 Leu-enk cell lines were produced and one, LE4H8, was chosen for characterization. | lld:pubmed |
| pubmed-article:7518482 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7518482 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7518482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7518482 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7518482 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:7518482 | pubmed:issn | 0022-1759 | lld:pubmed |
| pubmed-article:7518482 | pubmed:author | pubmed-author:WilsonG SGS | lld:pubmed |
| pubmed-article:7518482 | pubmed:author | pubmed-author:McCormackR... | lld:pubmed |
| pubmed-article:7518482 | pubmed:author | pubmed-author:LAYR GRG | lld:pubmed |
| pubmed-article:7518482 | pubmed:author | pubmed-author:WolfertR LRL | lld:pubmed |
| pubmed-article:7518482 | pubmed:author | pubmed-author:FrazerJ MJM | lld:pubmed |
| pubmed-article:7518482 | pubmed:author | pubmed-author:HendricksonT... | lld:pubmed |
| pubmed-article:7518482 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7518482 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:7518482 | pubmed:volume | 172 | lld:pubmed |
| pubmed-article:7518482 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7518482 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7518482 | pubmed:pagination | 165-72 | lld:pubmed |
| pubmed-article:7518482 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:meshHeading | pubmed-meshheading:7518482-... | lld:pubmed |
| pubmed-article:7518482 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7518482 | pubmed:articleTitle | Enhanced immunogenicity of leucine enkephalin following coupling to anti-immunoglobulin and anti-CD3 antibodies. | lld:pubmed |
| pubmed-article:7518482 | pubmed:affiliation | Department of Chemistry, University of Kansas, Lawrence 66045. | lld:pubmed |
| pubmed-article:7518482 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7518482 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7518482 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
